Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 189.86% from the stock’s previous close.
Context Therapeutics Trading Down 8.4 %
Shares of NASDAQ:CNTX traded down $0.19 during trading on Monday, reaching $2.07. The stock had a trading volume of 71,196 shares, compared to its average volume of 300,470. The firm’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $1.88. Context Therapeutics has a one year low of $0.77 and a one year high of $2.75. The company has a market capitalization of $155.25 million, a P/E ratio of -1.56 and a beta of 2.31.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Equities research analysts forecast that Context Therapeutics will post -0.31 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Stories
- Five stocks we like better than Context Therapeutics
- How to Invest in Small Cap Stocks
- The Average 401k Balance by Age Explained
- 5 Top Rated Dividend Stocks to Consider
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- The Most Important Warren Buffett Stock for Investors: His Own
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.